Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

Andrea Sartore-Bianchi,Filippo Pietrantonio,Sara Lonardi,Benedetta Mussolin,Francesco Rua,Elisabetta Fenocchio,Alessio Amatu,Salvatore Corallo,Chiara Manai,Federica Tosi,Paolo Manca,Francesca Daniel,Valter Torri,Angelo Vanzulli,Giovanni Cappello,Caterina Marchiò,Anna Sapino,Silvia Marsoni,Salvatore Siena,Alberto Bardelli

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

2021

3506Background: Despite advances in molecular segmentation of metastatic colorectal cancer (mCRC), beyond RAS status therapeutic actionability remains confined to the limited subgroups of ERBB2 amp...

Keywords:

Medicine
Colorectal cancer
Selection (genetic algorithm)
Phases of clinical research
Cancer research
Panitumumab
Circulating tumor DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations